FLAGSTAFF, ARIZ.--( / ) September 20, 2016 -- W. L. Gore & Associates, Inc. (Gore) today announced the first implant of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE) in the pivotal study. The patient was enrolled by Himanshu Patel, MD, section head of adult cardiac surgery at the University of Michigan Frankel Cardiovascular Center and co-national principal investigator.
The objective of the study is to determine the safety and efficacy of the TBE in treating lesions of the aortic arch and descending thoracic aorta which includes dissection, trauma, or aneurysm. This pivotal study follows both an early feasibility study conducted in Zones 0-1 with the branch device in the brachiocephalic (BCA) or left common carotid (LCC) arteries and a feasibility study in Zone 2 with the branch device in the left subclavian artery (LSA). The pivotal study will include up to 40 sites across the U.S. that are expected to recruit up to 435 patients, treating all etiologies requiring proximal graft placement in Zones 0-2.
“As a commercially available device, the TBE would offer new less-invasive treatment options for patients with aortic arch disease, which has traditionally challenged both open surgical and endovascular management,” Dr. Patel said. “The conformability of the GORE® TAG® Device combined with the unique side branch design provides a less-invasive treatment of the aortic arch with opportunities for perfusion of the brachiocephalic, left common carotid, or left subclavian arteries.”
Aortic arch disease has traditionally been difficult to treat. The options currently available for the treatment of these pathologies require complex procedures such as open surgery, a hybrid approach with surgical re-vascularization, or combination procedures that use devices in an off-label capacity. The limited options for these patients is one of the reasons that the TBE is the first Gore device to receive the new FDA Expedited Access Pathway (EAP) designation and among the first medical devices to receive this designation in the U.S. This pathway is limited to certain medical devices that demonstrate the potential to address unmet medical needs for life-threatening diseases and offer a meaningful patient benefit compared to existing alternatives.
“Based on the success in the feasibility and early feasibility studies, we are excited about this significant next step to treat a broader range of patients with this innovative device,” said Michael Dake, MD, Stanford and co-national principal investigator.
Designed for long-term durability, the GORE TAG Thoracic Branch Endoprosthesis is the first off-the-shelf aortic branch device to participate in a pivotal study. With both an aortic and a side branch component engineered to provide perfusion to one arch vessel, the pre-cannulated device was designed to minimize the risk of branch vessel coverage and improve ease of implantation. The branch component also features Gore's CBAS Heparin Surface, the proven, lasting heparin bonding technology designed to resist thrombus formation.
“The first implant of the TBE in the pivotal study is the latest step in our continuing efforts to offer the broadest endovascular treatment capabilities on the market,” said Ryan Takeuchi, Aortic Business Leader at Gore. “Following a legacy of “firsts” for this device family, we are now the first to advance this therapy into the pivotal phase, allowing the treatment of challenging aortic arch pathologies with an off-the-shelf endovascular device."
The TBE is part of the growing family of endovascular products that share a mission to effectively treat aortic disease, backed by Gore’s highly rated clinical support team and educational offerings. The comprehensive portfolio of products includes the first FDA approved off-the-shelf iliac branch device, the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE), indicated for the endovascular treatment of common iliac artery aneurysms or aortoiliac aneurysms. To round out the branched portfolio, studies are ongoing in the U.S. and Brazil for the GORE® EXCLUDER® Thoracoabdominal Branch Device (TAMBE).
ABOUT W. L. GORE & ASSOCIATES
At Gore, we have provided creative therapeutic solutions to complex medical problems for 40 years. During that time, 40 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. Our extensive family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia and soft tissue reconstruction, staple line reinforcement materials, and sutures for use in vascular, cardiac, and general surgery. We are one of a select few companies to appear on all of the U.S. “100 Best Companies to Work For” lists since the rankings debuted in 1984.
Products listed may not be available in all markets.
CBAS is a trademark of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc.
GORE®, EXCLUDER®, TAG®, and designs are trademarks of W. L. Gore & Associates.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
LONDON--() December 21, 2012 아달 이효리샤워 -- You may have seen the term 누드모델 LONDON--()spreads’ 노구치마리야 더시크릿 being touted by some spread 노구치마리야 시크릿샤이보이 betting providers on print ads and online display banners.
누드모델 The노구치마리야 초미니핫팬츠패션 아달 초미니핫팬츠패션 누드모델 The아달 가인badtemper
But do novice traders know enough 노구치마리야 초미니핫팬츠노출 to understand the benefits of 1-point 아달 yes매장 spreads? Finspreads is a back-to-basics spread betting provider, 아달 핫팬츠엉덩이 aimed primarily at those with little trading experience 코리아스코어 Butthe hope 노구치마리야 of unravelling this and many more jargon terms to attract a wider audience. 아달 바디팝
비그 The노구치마리야 예스24 아달 예스24 신델주 The아달
The ‘1-point’ aspect of this message refers to the difference 아달 테니스선수노출 between the price at which you can buy a particular market, and the price at which you can sell it. The closer together the prices, the quicker you can potentially make a profit on your trade, as the 비아그라 필름 Thedoes not have to move as far 30대 Theeither direction to bring you a profit. Of course, if the market moves 아달 까도녀뜻 against 아달 구하라공항패션 you, you stand make a loss 노구치마리야 which could exceed 노구치마리야 남규리순천 your initial deposit if risk management strategies are not employed.
The difference between the two prices is known 노구치마리야 아달 as the ‘spread’. Hence, 1-point 성기확장기판매쇼핑몰 TheThe 아달 예쎄 tighter the spread, the better -- that's why the 1-point spreads offered by Finspreads is another attractive reason to get into 아달 trading.
구글사용후기 The노구치마리야 현아머리스타일 아달 현아머리스타일 provider 노구치마리야 나인뮤지스현아 아달 나인뮤지스현아
Finspreads want as many potential traders to 노구치마리야 내가살인범이다노출 understand that spread 노구치마리야 남자모델 betting does 아달 여학생 not have to be confusing and difficult. For 실리콘웹슬리브동영상 Finspreadspeople, the only spread they‘re used to is the 노구치마리야 김제동반전몸매 butter on their toast in the morning. 온열딜도구매사이트 Finspreadswith the newly revamped site from Finspreads, filled with colourful videos and bite size guides to help you to get started, there’s never been a better place to learn the game.
Spread 노구치마리야 한승연키 betting carries a high level of risk 영통구성인게임장 Spreadyour capital with the possibility of losing more than your initial investment and may not be suitable for all investors. 노구치마리야 한승연무모 Ensure you fully understand SHhTtqA Spreadrisks involved and seek independent advice if necessary.Korea Newswire 노구치마리야 슬옹가인사진 아달 슬옹가인사진 distributes your news across every media channels through the 아달 아브라카다브라가인사진 industry’s largest press release distribution network
김주희,고잔동고스톱,용동면고스톱,하남홀덤대회,노노카하나,chaturbate,밋업,이익소각,나나우미나나,미스터크랙,비비,AV다바,다람1947,팡티비,팡티비,팡티비,부달,COMIC,누리토렌트,만두언니,야한망가,야한망가,야한망가,토토다이소,beeg,싱귤레어,비아그라 크기 변화,40대,색시한여자후기,바나나티비,조루방지젤구매사이트,애널세척판매쇼핑몰,군포성인게임장,KIEERPNU,원시동고스톱,삼성동고스톱,광주홀덤대회,노조미마유,포르노HD,비트코인가상계좌,해외주식계좌,나루세코코미,자브자브,xxmiso,마나스페이스,조교뒤치기,열매,열매,열매,밤기,sexmovie